Search results for "Antibodies"

showing 10 items of 1885 documents

Cardiovascular Events in Rheumatoid Arthritis-Time to See Beyond Articular Involvement in "Real World" Clinical Practice: Comment on the Article by M…

2015

medicine.medical_specialtyImmunologyMEDLINEArthritisCoronary DiseasePeptides CyclicLeft ventricular massArthritis RheumatoidRheumatologyInternal medicinemedicineImmunology and AllergyHumansDiastolic functionStrokeAutoantibodiesbusiness.industryAutoantibodymedicine.diseaseAutoantibodieClinical PracticeStrokeRheumatoid arthritisCardiologyFemalebusinessHumanArthritisrheumatology (Hoboken, N.J.)
researchProduct

The Presence of Gestational Diabetes is Associated with Increased Detection of Anti-HLA-class II Antibodies in the Maternal Circulation

2006

Problem Gestational diabetes (GD) may be associated with temporarily reduced immune tolerance toward alloantigens for the time of pregnancy. The aim of this study was to assess anti-HLA-class I and -II antibodies as markers for an aberrant immunostimulation in women with GD. Method of study The percentage of anti-HLA-class I and -II antibodies was estimated in women with GD, normal term delivery and fetal distress, which was confirmed by demonstrating low cord blood pH for this patient group. These antibodies may cross the placental barrier and cause interleukin-6 (IL-6) release from fetal monocytes by cross-linking monocytes with antibody-loaded cells. Therefore we estimated the percentage…

medicine.medical_specialtyImmunologyModels BiologicalFetal DistressAntigenIsoantibodiesPregnancyInternal medicinemedicineFetal distressHumansImmunology and AllergyFetusPregnancybusiness.industryHistocompatibility Antigens Class IIObstetrics and GynecologyHydrogen-Ion ConcentrationFetal Bloodmedicine.diseaseGestational diabetesDiabetes GestationalTolerance inductionFetal circulationEndocrinologyReproductive MedicineCord bloodLeukocytes MononuclearFemalebusinessAmerican Journal of Reproductive Immunology
researchProduct

Safety and tolerability of omalizumab

2009

Summary Background Omalizumab (Xolair®) is a recombinant humanized monoclonal anti-IgE antibody with proven efficacy in patients with moderate-to-severe and severe persistent allergic (IgE-mediated) asthma. Objective To review clinical study data to assess the safety profile of omalizumab. Methods We analysed the safety of omalizumab using data from completed clinical studies (up to 1 year) involving more than 7500 patients with asthma, rhinitis or related conditions and up to 4 years in one study of patients with severe allergic asthma, as well as post-marketing safety data. Analysis focuses on the risk of immune-system effects, hypersensitivity reactions, malignant neoplasia, parasitic in…

medicine.medical_specialtyImmunologyOmalizumabOmalizumabChurg-Strauss SyndromeAntibodies Monoclonal HumanizedInfectionsImmunoglobulin EAnti-asthmatic AgentNeoplasmsInternal medicinemedicineHumansImmunology and AllergyAnti-Asthmatic AgentsAnaphylaxisAsthmaClinical Trials as Topicbiologybusiness.industryIncidence (epidemiology)Antibodies Monoclonalmedicine.diseaseThrombocytopeniaAsthmaAntibodies Anti-IdiotypicClinical trialTolerabilityImmunologybiology.proteinbusinessAnaphylaxismedicine.drugClinical & Experimental Allergy
researchProduct

Ocular surface disease during dupilumab treatment in patients with atopic dermatitis, is it possible to prevent it?

2020

medicine.medical_specialtyInterleukin-13Ocular surface diseasebusiness.industryMEDLINEEczemaDermatologyAtopic dermatitismedicine.diseaseAntibodies Monoclonal HumanizedDupilumabDermatologyDermatitis Atopicdupilumab atopic dermatitis ocular surface diseaseInfectious DiseasesmedicineHumansIn patientbusinessJournal of the European Academy of Dermatology and Venereology : JEADV
researchProduct

Autoimmunity and Glaucoma

2008

Elevated intraocular pressure does not explain glaucoma in all patients, but there is information that autoimmune mechanisms may be involved in this disorder. This review attempts to reveal the findings about specific changes in autoantibody profiles in glaucoma patients and their possible role in glaucoma. Considering that these changes in natural autoimmunity can be found consistently among different study populations, it might be a promising new tool for glaucoma detection.

medicine.medical_specialtyIntraocular pressuregenetic structuresbusiness.industryAutoantibodyGlaucomaAutoimmunityGlaucomamedicine.disease_causemedicine.diseaseeye diseasesAutoimmune DiseasesAutoimmunityOphthalmologyElevated intraocular pressureOphthalmologymedicineHumanssense organsbusinessIntraocular PressureAutoantibodiesJournal of Glaucoma
researchProduct

Reply to Drs. Kiaei and Molinaro Regarding the Publication “Comparison of a Bridge Immunoassay with Two Bioassays for Thyrotropin Receptor Antibody D…

2020

Dear Editor,Drs. Kiaei and Molinaro 1 put forth two criticisms of the manuscript published by us 2. They state that the experimental design of this study is flawed and that the authors falsely claim that negative Thyretain™ TSI Reporter BioAssay results for two Graves’ diseases patients undergoing drug treatments means the absence of stimulating antibodies. To substantiate this claim Drs. Kiaei and Molinaro point out that the manufacturer of the Thyretain TSI Reporter BioAssay clearly states in the package insert that “[t]he effects of various drug therapies on the performance of this Kit have not been established” 1. Second, the package insert explicitly states that “[a] negative result do…

medicine.medical_specialtyLetter to the editorPackage insertEndocrinology Diabetes and MetabolismClinical BiochemistryThyrotropin receptor Antibody030209 endocrinology & metabolismBiochemistryAntibodies03 medical and health sciences0302 clinical medicineEndocrinologyClinical historyInternal medicineClinical informationHumansMedicineBioassayLetter to the EditorImmunoassaymedicine.diagnostic_testbusiness.industryBiochemistry (medical)Receptors ThyrotropinGeneral MedicineGraves DiseasePatient population030220 oncology & carcinogenesisImmunoassaybusinessImmunoglobulins Thyroid-StimulatingHormone and Metabolic Research
researchProduct

New approaches in the treatment of Adamantiades-Behçet's disease.

2005

Purpose of review To update clinicians on the recent advances in the treatment of Adamantiades-Behcet's disease. Recent findings Interferon-α-2a and infliximab have proved able to induce prompt remission in the vast majority of Adamantiades-Behcet's patients with DMARD-resistant uveoretinitis. Efficacy of interferon-α-2a has also been reported for mucocutaneous lesions, arthritis, and (more anecdotally) for neuro-Behcet, while results from small case series suggest that infliximab is beneficial for mucocutaneous lesions and (more anecdotally) for arthritis and gastro-intestinal manifestations. Two cases of neuro-Behcet treated with infliximab showed a complete resolution. Finally, in a rand…

medicine.medical_specialtyMucocutaneous zoneArthritisBehcet's diseaseDiseaseInterferon alpha-2Receptors Tumor Necrosis Factorlaw.inventionEtanerceptEtanerceptRheumatologyRandomized controlled triallawAntibodies Monoclonal; Behcet Syndrome; Chaperonin 60; Humans; Immunoglobulin G; Immunologic Factors; Interferon-alpha; Receptors Tumor Necrosis Factor; Recombinant ProteinsmedicineHumansImmunologic FactorsIFN-α2abusiness.industryBehcet SyndromeAntibodies MonoclonalInterferon-alphaChaperonin 60medicine.diseaseDermatologyeye diseasesInfliximabAdamantiades-Behçet's diseaseInfliximabRecombinant Proteinsstomatognathic diseasesImmunoglobulin GImmunologyTumour necrosis factorbusinessTolerizationUveitismedicine.drugCurrent opinion in rheumatology
researchProduct

Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort

2021

Abstract Objective The objective of this study was to use real-world data to evaluate the effectiveness and safety of canakinumab in Italian patients with systemic JIA (sJIA). Methods A retrospective multicentre study of children with sJIA was performed. Clinical features, laboratory parameters and adverse events were collected at baseline, and 6 and 12 months after starting canakinumab. The primary outcome measure of effectiveness was clinically inactive disease (CID) off glucocorticoids (GCs) treatment at 6 months. Results A total of 80 children from 15 Italian centres were analysed. Of the 12 patients who started canakinumab in CID while receiving anakinra, all maintained CID. Of the 68 …

medicine.medical_specialtyMultivariate analysissystemic juvenile idiopathic arthritisArthritisJuvenileAntibodies Monoclonal HumanizedcanakinumabAntibodiessystemic juvenile idiopathic arthritis.Settore MED/38 - Pediatria Generale E SpecialisticaRheumatologyInternal medicineMonoclonalmedicinecanakinumab; clinically inactive disease; systemic juvenile idiopathic arthritis; Antibodies Monoclonal Humanized; Child; Glucocorticoids; Humans; Retrospective Studies; Arthritis Juvenile; Macrophage Activation SyndromeHumanscanakinumab clinically inactive disease systemic juvenile idiopathic arthritis Antibodies Monoclonal Humanized Child Glucocorticoids Humans Retrospective Studies Arthritis Juvenile Macrophage Activation SyndromePharmacology (medical)clinical inactive disease.Adverse effectChildHumanizedGlucocorticoidsRetrospective StudiesUnivariate analysisAnakinrabusiness.industryclinically inactive diseaseArthritisMacrophage Activation Syndromemedicine.diseaseArthritis JuvenileCanakinumabMacrophage activation syndromeCohortSystemic juvenile idiopathic arthritibusinessmedicine.drug
researchProduct

Migraine and cluster headache – the common link

2018

Abstract Although clinically distinguishable, migraine and cluster headache share prominent features such as unilateral pain, common pharmacological triggers such glyceryl trinitrate, histamine, calcitonin gene-related peptide (CGRP) and response to triptans and neuromodulation. Recent data also suggest efficacy of anti CGRP monoclonal antibodies in both migraine and cluster headache. While exact mechanisms behind both disorders remain to be fully understood, the trigeminovascular system represents one possible common pathophysiological pathway and network of both disorders. Here, we review past and current literature shedding light on similarities and differences in phenotype, heritability…

medicine.medical_specialtyNeurologyCluster headacheImplantable Neurostimulators/statistics & numerical dataPain medicineCalcitonin Gene-Related PeptideDeep Brain StimulationMigraine DisordersNitroglycerin/adverse effectsHypothalamuslcsh:MedicineTriptansReviewCalcitonin gene-related peptideBioinformatics03 medical and health sciencesNitroglycerin0302 clinical medicinemedicineHumans030212 general & internal medicineTryptamines/pharmacologyMigraineTrigeminovascular systembusiness.industryNeuromodulationCluster Headache/bloodCluster headacheAnti-CGRP (receptor) monoclonal antibodies – mAbsMigraine Disorders/bloodTrigeminovascular systemlcsh:RGeneral MedicineCalcitonin gene-related peptide (CGRP)medicine.diseaseDeep Brain Stimulation/statistics & numerical dataNeuromodulation (medicine)Tryptamines3. Good healthCalcitonin Gene-Related Peptide/antagonists & inhibitorsAnesthesiology and Pain MedicineImplantable NeurostimulatorsMigraineNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugThe Journal of Headache and Pain
researchProduct

Long-Term Evaluation of a Rat Model of Chronic Cholangitis Resembling Human Primary Sclerosing Cholangitis

2003

Primary sclerosing cholangitis (PSC) is a chronic cholestatic disorder with a presumed autoimmune aetiopathogenesis. We have recently described a novel organ-specific rat model of fibrosing cholangitis induced by intrabiliary administration of the hapten-reagent 2,4,6-trinitrobenzenesulfonic acid (TNBS) with similarities to human PSC. In the present report, we have evaluated the long-term outcome of TNBS-induced cholangitis in this model. Mild stenosis of the common bile duct of female Lewis rats (n = 18) was achieved by subtotal ligation and cholangitis induced by TNBS injection (50 mg/kg) into the dilated bile duct after a second laparotomy. After 8 and 12 months, we found no evidence of …

medicine.medical_specialtyPathologyNecrosisCholangitis SclerosingImmunologyInflammationdigestive systemGastroenterologyAntibodies Antineutrophil CytoplasmicPrimary sclerosing cholangitisCholangiographyInternal medicinemedicineAnimalsHumansChronic CholangitisAnti-neutrophil cytoplasmic antibodymedicine.diagnostic_testCommon bile ductbusiness.industryAlanine TransaminaseGeneral Medicinemedicine.diseaseRatsDisease Models AnimalC-Reactive Proteinmedicine.anatomical_structureLiverTrinitrobenzenesulfonic AcidRats Inbred LewChronic DiseaseDisease ProgressionFemalemedicine.symptomLigationbusinessScandinavian Journal of Immunology
researchProduct